Tracing Neurological Diseases in the presymptomatic phase: moving forward a detection panel
1Institut de génomique fonctionnelle, Inserm, CNRS, Université de Montpellier, Montpellier, France; Service de neurologie, CHU de Nimes, Nimes, France.
Revue Neurologique
|November 14, 2025
Summary
Presymptomatic biomarkers for neurodegenerative diseases like Alzheimer's and Parkinson's are advancing, enabling earlier detection and intervention. Combining multiple markers and using blood tests shows promise for proactive neurological care.
Area of Science:
- Neurology
- Biomarker Research
- Neurodegenerative Diseases
Background:
- Neurodegenerative diseases (Alzheimer's, Parkinson's, FTD, ALS, MS) have long presymptomatic phases.
- Neuropathological changes occur silently before clinical symptoms emerge.
- Early intervention is critical but challenging due to late diagnosis.
Purpose of the Study:
- To review promising presymptomatic biomarkers for major neurodegenerative diseases.
- To highlight their biological basis, diagnostic accuracy, and clinical use.
- To explore the potential of biomarker panels and minimally invasive methods.
Main Methods:
- Literature review synthesizing current knowledge on presymptomatic biomarkers.
- Analysis of molecular and imaging signatures.
- Evaluation of biomarker panels and blood-based assays.
Main Results:
- Biomarkers offer molecular and imaging signatures preceding clinical onset.
- Biomarker panels enhance diagnostic sensitivity and specificity.
- Minimally invasive assays show potential for screening and monitoring.
Conclusions:
- Presymptomatic biomarkers are crucial for early detection and intervention in neurodegenerative diseases.
- Biomarker panels and blood tests can improve diagnostic accuracy.
- Standardization and collaboration are key for clinical integration and proactive neurology.
